Orig3n Inc, a Boston-based biotech company involved in genetics and regenerative medicine research, has acquired Interleukin Genetics CLIA laboratory and its remaining assets, it was reported yesterday.
The acquisition is intended to allow Interleukin Genetics' technology to become a core component of Orig3n's DNA test business.
The automated genotyping lab is completely-licensed for testing in all 50 US states and is capable of processing over one million samples per annum. In addition to the company's technology and its HIPAA and HITECH compliance, Interleukin Genetics also provides Orig3n with its ILUSTRA Inflammation Management Program and its Inherent Health genetic tests for nutritional needs, weight management, heart health, and bone health.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA